News Focus
News Focus
icon url

Work Harder

03/04/22 10:52 PM

#26525 RE: Phosphene #26494

@ least they didn't

trade on it

:}

Praying for you brother & all that comes w/ that
icon url

Work Harder

03/07/22 12:04 PM

#26544 RE: Phosphene #26494

Why is Kempers & Stegamnn

doing biz of sorts in Romania, paying taxes ?

Jan Wilschut

Scientific Advisory Board
Drexel University
Romania

https://biography.omicsonline.org/romania/drexel-university/jan-wilschut-1230296

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160090159

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160091622

Fwiw H.C. Wainwright downgraded Grant Pickering's Ettx yesterday
icon url

Work Harder

03/07/22 12:28 PM

#26545 RE: Phosphene #26494

Trial coming brother

Or Moderna & Vir will have to move into pre-clinical after this b/c Dr turn around expert specialist has raised the bar for them on that

LOL

Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform

https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-initiation-phase-1-clinical-trial

CLINICAL CORE

The Clinical Research Core will provide the personnel and administrative support to conduct clinical trials and other clinical research activities related to medical cannabis.

It will leverage Drexel’s clinical expertise and the availability of patients with qualifying conditions for medical cannabis such as, but not limited to, HIV, neuropathies, and PTSD.

The clinical core will launch in early 2022.

https://drexel.edu/cannabis-research/research/projects/

Quality of life in people living with HIV in Romania and Spain

https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06567-w

Introducing HIV Outcomes Romania

https://hivoutcomes.eu/introducing-hiv-outcomes-romania/

Members

https://hivoutcomes.eu/about-us/team-members/

Gotta wonder wonder what happened w/ Fruci and Associates, the sec attorney & their mary jane company trip to Swazzyland last month, eh.